Equities Analysts Set Expectations for CTXR FY2024 Earnings

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – HC Wainwright cut their FY2024 earnings per share estimates for Citius Pharmaceuticals in a report issued on Tuesday, November 12th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($0.26) per share for the year, down from their prior forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Citius Pharmaceuticals’ current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.18) EPS.

Citius Pharmaceuticals Trading Down 14.9 %

Shares of CTXR opened at $0.33 on Thursday. The stock has a market capitalization of $59.35 million, a price-to-earnings ratio of -1.61 and a beta of 1.66. Citius Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $1.07. The firm has a fifty day simple moving average of $0.44 and a 200 day simple moving average of $0.60.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01).

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its position in shares of Citius Pharmaceuticals by 88.5% in the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after buying an additional 32,686 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Citius Pharmaceuticals in the 2nd quarter valued at $29,000. Arkadios Wealth Advisors raised its stake in Citius Pharmaceuticals by 33.3% in the 3rd quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock valued at $100,000 after acquiring an additional 50,000 shares during the period. Wealth Advisory Solutions LLC lifted its holdings in Citius Pharmaceuticals by 33.1% during the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Citius Pharmaceuticals by 1.5% during the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after purchasing an additional 104,889 shares during the period. 16.88% of the stock is currently owned by institutional investors and hedge funds.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.